Among pediatric CNS tumors, all illustrated lower expression of FOLH1 in at least two dose-limiting tissues with the exception of oligodendrogliomas, whose FOLH1 expression was either similar to or higher than that of the dose-limiting tissues of interest (Figure 4B, Supplementary Table S2). This evidence concerns the gene FOLH1 and oligodendroglioma.